Atopic dermatitis (AD) is a chronic disease driven by persistent underlying inflammation2–4

Adults with moderate-to-severe AD report a multi-dimensional burden including loss of sleep, quality of life, and psychosocial effects5–7

Nonlesional skin in AD is not normal skin2–4

Normal Skin

Nonlesional Skin

Lesional Skin

AD experts* proposed four types of treatment failure which patients with AD may experience despite appropriate dose, duration and adherence to a therapeutic agent:5


Inadequate clinical



Failure to achieve
stable long-term
disease control5


Adverse events or
poor tolerability with
current treatment5


Failure to relieve
burden of disease†5


  • Adult Patient-Reported Outcomes:‡7

    Patient reported outcomes in uncontrolled AD

  • Adolescent (14–17 years old) Patient-Reported Outcomes:§8

    Patient reported outcomes in uncontrolled AD

The burden of inadequately controlled AD may become chronic, even cumulative, impacting patients throughout their lives2,6,8

Mode of action DUPIXENT

Have questions about how DUPIXENT works?

Find out more

Request a representative call

Have aquestion about DUPIXENT?
Get answers from a representative.

Find out more

Inflammatory pathways

What are the main inflammatory pathways involved in the disease? Find out about the pathway involved in AD.

Find out more

    *A steering committee that consisted of a multi-disciplinary group of AD experts, including 8 dermatologists, two allergists and a patient advocacy group representative. This group met to identify and prioritise a number of essential questions concerning the evaluation and management of moderate-to-severe AD in the era of biologic therapies.5
    Presence of ongoing impairment (e.g., pruritus, pain, loss of sleep, and poor quality of life) while on treatment.5
    These results are patient-reported outcomes collected at a screening for a Phase 2b clinical trial of DUPIXENT (n=380).7
    §These results are patient-reported outcomes from the ISOLATE study collected in six countries by in-depth telephone interviews. Questions were developed in collaboration with national eczema patient groups and physicians. Figures reported are from patients aged between 14–17 years (n=125).8
    ||A flare is defined as a sudden worsening of symptoms requiring consultation or application of prescription medication.8
    Parent self-reported survey of their children aged 6–11 years with severe AD (n=39) (2018–2019), from Europe.9
    #The NRS score was on a scale of 0–10; higher scores indicate worse sleep severity, reported in the last 24 hours.9
    **A survey from Allergy UK of patients with severe AD ran from the 15th November 2016 until the 9th December 2016. The number of respondents to the survey was 305. Not all respondents gave an answer to every question.11

    AD, atopic dermatitis; ISOLATE, International Study of Life with Atopic Eczema; NRS, Numerical Rating Scale.


    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Leung DYM, et al. J Clin Invest. 2004;113(5):651–657.
    3. Suárez-Fariñas M, et al. J Allergy Clin Immunol. 2011;127(4):954–964.
    4. Gittler JK, et al. J Allergy Clin Immunol. 2012;130(6):1344–1354.
    5. Boguniewicz M, et al. J Allergy Clin Immunol Pract. 2017;5:1519–1531.
    6. Ibler K & Jemec. GBE Dermatol Rep. 2011;3:e5.
    7. Simpson EL, et al. J Am Acad Dermatol. 2016;74(3):491–498.
    8. Zuberbier T, et al. J Allergy Clin Immunol. 2006;11(1):226–232.
    9. Weidinger S, et al. The Patient-Reported Disease Burden in Pediatric Patients with Atopic Dermatitis (AD): A Cross-Sectional Study in the United States (US), Canada, Europe, and Japan. (Poster) Presented at the American Academy of Dermatology (AAD) Annual Meeting, Denver, CO, USA, March 20–24 2020.
    10. Stocker RPJ, et al. Arch Clin Neuropsychol. 2017;32:349–368.
    11. (2019). Available at: Red_Report_FINAL_25.04.17_original.pdf?1508228476. Date accessed: September 2021.
    12. Bantz SK, et al. J Clin Cell Immunol. 2014;5(2):202.
    13. Irvine AD, et al. Br J Dermatol. 2019;181:895–906.

MAT-IE-2101040(v4.0) | Date of preparation: February 2022